Modulators of leukotriene biosynthesis and receptor activation

Journal of Medicinal Chemistry

Volumn 39, Issue 14, 1996, Pages 2629-2654

  Brooks, Clint D W ^a   Summers, James B ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 (2 QUINOLYLMETHOXY)ANILINO]BENZOIC ACID; 2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [(2 CARBOXYETHYL)THIO] 3 [2 (8 PHENYLOCTYL)PHENYL]PROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 CARBOXYPHENYLTHIO) 7 [4 (4 PHENOXYBUTOXY)PHENYL] 5 HEPTENOIC ACID; 4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLSULFONYL] 3 OXO 4 PHENYLBUTYRIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLTHIO]PHENYL] 4 HYDROXY 3 METHYLBUTYRIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; 7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID; ACETYLSALICYLIC ACID; ALPHA METHYL 6 (2 QUINOLYLMETHOXY) 2 NAPHTHYLACETIC ACID; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; L 668019; LEUKOTRIENE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; N [3 (3 PHENOXYPHENYL)ALLYL]ACETOHYDROXAMIC ACID; POBILUKAST; PRANLUKAST; RITOLUKAST; STEROID; SULUKAST; TOMELUKAST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENZAIR; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

AIRWAY OBSTRUCTION; ALLERGY; ARACHIDONIC ACID METABOLISM; ASTHMA; BIOSYNTHESIS; BRONCHOSPASM; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOASSAY; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROVOCATION TEST; REVIEW; STRUCTURE ACTIVITY RELATION; TOPICAL DRUG ADMINISTRATION; ULCERATIVE COLITIS;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CARRIER PROTEINS; FORECASTING; HUMANS; LEUKOTRIENE B4; LEUKOTRIENES; MEMBRANE PROTEINS; MOLECULAR STRUCTURE; RECEPTORS, LEUKOTRIENE;

EID: 0029946682     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960088k     Document Type: Review

References (297)

1. Samuelsson, B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983, 220, 568-575.
2. Corey, E. J.; Niwa, H.; Falck, J. R.; Mioskowski, C.; Arai, Y.; Marfat, A. Recent studies on the chemical synthesis of eicosanoids. Adv. Prostaglandin Thromboxane Res. 1980, 6, 19-25.
3. Borgeat, P.; Sirois, P. Leukotrienes: a major step in understanding immediate hypersensitivity reactions. J. Med. Chem. 1981, 24, 121-126.
4. Shaw, A.; Krell, R. D. Peptide leukotrienes: current status of research. J. Med. Chem. 1991, 34, 1235-1242.
5. Musser, J. H.; Kreft, A. F. 5-Lipoxygenase: properties, pharmacology and the quinolinyl(bridged)aryl class of inhibitors. J. Med. chem. 1992, 35, 2502-2524.
6. Orange, R. P., Austen, K. F. Slow reacting substance of anaphylaxis. Adv. Immunol.
7. Leuktrienes and other products of the 3-hpoxygenase pathway. New Engl. J. Med. 1990, 323, 645-655.
8. Henderson, W. R. The role of leukotrienes in inflammation. Ann. Intern. Med. 1994, 121, 684-697.
9. 4. J. Biol. Chem. 1984, 259, 11403-11407.
10. Rouzer, C. A.; Samueisson, B. Leukocyte arachidonate 5-lipoxygenase isolation and characterization. Methods Enzymol. 1990, 187, 312-319
11. Steinhilber, D, S-Lipoxygenase, enzyme expression and regulation of activity, Pharm. Acta Helv. 1994, 69, 3-14.
12. Rouzer, C. A.; Samuelsson, B. On the nature of the 5-lipoxygenase reaction in human leukocytes: Enzyme purification and requirement for multiple stimulatory factors. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 6040-6044.
13. Falgueyret, J.-P.; Denis, D.; Macdonald, D.; Hutchinson, J. H.; Riendeau, D. Characterization of the arachidonate and ATP binding sites of human 5-lipoxygenase using photoaffinity labeling and enzyme immobilization. Biochemistry 1995, 34, 13603-13611.
14. 3-lipoxygenase. J. Lipid Med. Cell 12, 171-184
15. Chen, X-S.; Naumann, T. A.; Kurre, U.; Jenkins, N. A.; Copeland, N. G.; Funk, C. D, cDNA cloning, expression, mutagenesis, intracellular localization, and gene chromosomal assignment of mouse 5-lipoxygenase. J. Biol. Chem. 1995, 270, 17993-17999.
16. Goulet, J. L.; Snouwaert, J. N.; Latour, A. M.; Coffman, T. M.; Koller, B. H. Altered inflammatory responses in leukotriene-deflcient mice. Proc. Natl. Acad, Sci. U.S.A. 1994, 91, 12852-12856.
17. Corey, E. J.; Cashman, J. R.; Kanter, S. S.; Corey, D. R. Rationally designed, potent competitive inhibitors of leukotriene hiosynthesis. J. Am. Chem. Soc. 1984, 1503-1504.
18. S. P.; Dyer, R. D.; Carter G. W. hydroxainates inhibitors of 5-lipoxygenase. Tetrahedron Lett. 1985, 18, 2143-2146.
19. Kerdesky, F. A. J.; Schmidt, S. P.; Holms, J. H.; Dyer, R. D.; Carter, G. W.; Brooks, D. W. Synthesis and 5-lipoxygenase inhibitory activity of 5-hydroperoxy-6,8,11,14-eicosatetraenoic acid analogues. J. Med. Chem. 1987, 30, 1177-1186.
20. Haviv, F.; Ratajczyk, J. D.; DeNet, R. W.; Martin, Y. C.; Dyer, R. D.; Carter, G. W. Structural requirements for the inhibition of 5-lipoxygenase by 15-hydroxyeicosa-5,8,11,13-tetraenoic acid analogues. J. Med. Chem. 1987, 30, 254-263.
21. Summers, J. B.; Gunn, B. P.; Mazdiyasni, H.; Goetze, A. M.; Young, P. R.; Bouska, J. B.; Dyer, R. D.; Brooks, D. W.; Carter, G. W. In vivo characterization of hydroxamic acid inhibitor of 5-lipoxygenase. J. Med. Chem. 1987, 30, 2121-2126.
22. Summers, J. B.; Gunn, B. P.; Martin, J. G.; Mazdiyasni, H.; Stewart, A. O.; Young, P. R.; Goetze, A. M.; Bouska, J. B.; Dyer, R. D.; Brooks, D. W.; Carter, G. W. Orally active hydroxamic acid inhibitors of leukotriene biosynthesis. J. Med. Chem. 1988, 31, 3-5.
23. Summers, J. B.; Gunn, B. P.; Martin, J. G.; Martin, M. B.; Mazdiyasni, H.; Stewart, A. O.; Young, P. R.; Bouska, J. B.; Goetze, A. M.; Dyer, R, D.; Brooks, D. W.; Carter, G. W. Structure-activity analysis of a class of orally active hydroxamic acid inhibitor of leukotriene biosynthesis. J. Med. Chem. 1988, 31, 1960-1964.
24. Jackson, W. P.; Islip, P. J.; Kneen, G.; Pugh, A.; Wates, P. J. Acetohydroxamic acids as potent, selective, orally active 5-lipoxygenase inhibitors; J. Med. Chem. 1988, 31, 499-500.
25. Salmon, J. A.; Jacksoh, W. P.; Garland, L. G. Inhibition of 5-lipoxygenase: development of hydroxamic acids and hydroxyureas as potential therapeutic agents. Adv. Prostaglandin Thromboxane Res, 1990, 21, 109-112.
26. McMillan, R. M.; Walker, E. R. H. Designing therapeutically effective 5-lipoxygenase inhibitors. Trends. Pharmacol. Sci. 1992, 13, 323-330.
27. Brooks, D. W.; Summers, J. B.; Gunn, B. P.; Rodriques, K. E.; Martin, J. G., Martin, M. B.; Mazdiyasni, H.; Holms, J. H.; Stewart, A. O.; Moore J. L.; Young, P. R.; Albert, D. H.; Bouska, J. B.; Malo, P. E.; Dyer, R. D.; Bell, R. L.; Rubin, P.; Kesterson, J.; Carter, G. W. The discovery of A-64077, a clinical candidate for treating diseases invoiving ieukotriene mediators. Abstracts of the International Chemical Congress of Pacific Basin Societies, Honolulu, HI, 1989; BIOS 34.
28. Carter, G. W.; Young, P. R.; Albert, D. H.; Bouska, J.; Dyer, R.; Bell, R. L.; Summers, J. B.; Brooks, D. W.; Rubin, P.; Kesterson, J. A-64077, a new orally active 5-lipoxygenase inhibitor. In Leukotrienes and Prostanoids in Health and Disease, New Trends in Lipid Mediators Research; Zor, U., Naor, Z., Danon, A., Eds.; Karger: Basel, 1989; Vol. 3, pp 50-55.
29. Carter, G. W.; Young, P. R.; Albert, D. H.; Bouska, J.; Dyer, R.; Bell, R. L.; Summers, J. B.; Brooks, D. W. 5-Lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther. 1991, 256, 929-937.
30. Brooks, D. W.; Carter, G. W. The discovery of zileuton. In The Search for Anti-Inflammatory Drugs; Merluzzi, V. J., Adams, J., Eds.; Birkhauser: Boston, 1995; Chapter 5, pp 129-160.
31. Stevens, R. W. Hydroxamate and hydroxyurea based leukotriene biosynthesis inhibitors for the treatment of inflammatory diseases. Curr. Opin. Ther. Patents 1992, 1151-1160.
32. Garland, L. G.; Salmon, J. A. Hydroxamic acids and hydroxyureas as inhibitors of arachidonate 5-lipoxygenase. Drugs Future 1991, 16, 547-558.
33. Read, N. G.; Astbury, P.; Evans, G. O.; Goodwin, D. A.; Rowlands, A. Nephrotic syndrome associated with N-hydroxyureas, inhibitors of 5-lipoxygenase. Arch. Toxicol. 1995, 69, 480-490.
34. 4 in human whole blood. Prostaglandins 1987, 33, 539-551.
35. Sweeney, F. J.; Eskra, J. D.; Carty, T. J. Development of a system for evaluating 5-lipoxygenase inhibitors using human whole blood. Prostaglandin Leukotriene Med. 1987, 73-93.
36. Rubin, P.; Dubé, L.; Braeckman, R.; Swanson, L.; Hanson, R.; Albert, D.; Carter, G. Pharmacokinetics, safety and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. In Progress in Inflammation, Research and Therapy; Ackerman, N. R., Bonney, R. J., Welton, A. F., Eds.; Birkhauser: Basel, 1991; pp 103-116.
37. Sirois, P.; Borgeat, P.; Lauziere, M.; Dubé, L.; Rubin, P. R.; Kesterson, J. Effect of zileuton (A-64077) on the 5-lipoxygenase activity of human whole blood ex vivo. Agents Actions 1991, 34, 117-120.
38. Salmon, J. A.; Garland, L. G. Leukotriene antagonists and inhibitors of leukotriene biosynthesis as potential therapeutic agents. Prog. Drug. Res. 1991, 37, 9-90.
39. 4 after antigen challenge and in acute asthma and allergic rhinitis Lancet 1989, 1, 584-588.
40. Wenzel, S. E.; Trudeau, J. B.; Kaminsky, D. A.; Cohn, J.; Martin, R. J.; Westcott, J. Y. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am. J. Respir. Crit. Care Med. 1995, 152, 897-905.
41. Knapp, H. R.; Murray, J. J. Leukotrienes as mediators of nasal inflammation. Adv. Prostaglandin, Thromboxane, Leukotriene Res. 1994, 22, 279-288.
42. 4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J. Invest. Dermatol. 1984, 83, 70-73.
43. Laursen, L. S.; Naesdal, J.; Bukhave, K.; Lauritsen, K.; Rask-Madsen, J. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1990, 335, 683-685.
44. Drazen, J. M.; Austen, F. K. Leukotrienes and airway responses. Am. Rev. Respir. Dis. 1987, 985-998.
45. Henderson, W. R. Role of leukotrienes in asthma. Ann. Allergy 1994, 72, 272-278.
46. Israel, E. Moderating the inflammation of asthma: inhibiting the production or action of products of the 5-lipoxygenase pathway. Ann. Allergy 1994, 72, 279-284.
47. Hui, K. P.; Taylor, I. K.; Taylor, G. W.; Rubin, P.; Kesterson, J.; Barnes, N. C.; Barnes, P. J. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991, 46, 184-189.
48. Kane, G.; Pollice, M.; Cohn, J.; Murray, J.; Fish, J.; Peters, C. Controlled trial of the effect of a 5-LO inhibitor on lung inflammation produced by segmental challenge. J. Allergy Clin. Immunol. 1994, 93, A129.
49. Kane, G. C.; Tollino, M.; Pollice, M.; Kim, C.-J.; Cohn, J.; Murray, J. J.; Dworski, R.; Sheller, J.; Fish, J. E.; Peters, S. P. Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor. Prostaglandins 1995, 50, 1-18.
50. Israel, E.; Dermarkarian, R.; Rosenberg, M.; Sperling, R.; Taylor, G.; Rubin, P.; Drazen, J. M. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N. Engl. J. Med. 1990, 323, 1740-1744.
51. Latimer, K. M.; O'Byrne, P.; Morris, M. M.; Roberts, R.; Hargreave, F. E. Bronchoconstriction stimulated by airway cooling: better protection with combined inhalation of terbutaline sulfate and cromolyn sodium than with either alone. Am. Rev. Respir. Dis. 1983, 128, 440-443.
52. Merland, N.; Cartier, A.; L'Archeveque, J.; Ghezzo, H.; Malo, J. L. Theophylline minimally inhibits bronchoconstriction induced by dry cold air inhalation in asthmatic subjects. Am. Rev. Respir. Dis. 1988, 137, 1304-1308.
53. Spector, S. L. Update on exercise-induced asthma. Ann. Allergy 1993, 71, 571-577.
54. Meltzer, S. S.; Rechsteiner, E. A.; Johns, M.; Cohn, J.; Bleecker, E. R. Inhibition of exercise-induced asthma by zileuton, a 5-lipoxygenase inhibitor. Am. J. Respir. Crit. Care Med. 1994, 149, A215.
55. Samter, M.; Beers, R. F. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann. Intern. Med. 1968, 68, 975-983.
56. Christie, P. E.; Tagari, P.; Ford, H. A.; Charlesson, S.; Chee, P.; Arm, J. P.; Lee, T. H. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am. Rev. Respir. Dis. 1991, 143, 1025-1029.
57. Israel, E.; Fischer, A. R.; Rosenberg, M. A.; Lilly, C. M.; Callery, J. C.; Shapiro, J.; Cohn, J.; Rubin, P.; Drazen, J. M. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am. Rev. Respir. Dis. 1993, 148, 1447-1451.
58. Dahlén, S.-E.; Nizankowska, E.; Dahlén, B.; Bochenek, G.; Kumlin, M.; Mastalerz, L.; Blomqvist, H.; Pinis, G.; Rásberg, B.; Swanson, L. J.; Larsson, L.; Dubé, L.; Stewnsvad, F.; Zetterström, O.; Szczeklik, A. The Swedish-Polish treatment study with the 5-lipoxygenase inhibitor zileuton in aspirin-intolerant asthmatics. Am. J. Respir. Crit. Care Med. 1995, 151, A376.
59. Israel, E.; Rubin, P.; Kemp, J. P.; Grossman, J.; Pierson, W.; Siegel, S. C.; Tinkelman, D.; Murray, J. J.; Busse, W.; Segal, A. T.; Fish, J.; Kaiser, H. B.; Ledford, D.; Wenzel, S.; Rosenthal, R.; Cohn, J.; Lanni, C.; Perlman, H.; Karahalios, P.; Drasen, J. M. The effect of inhibition of 5-lipoxygenase by zileuton in mildto-moderate asthma. Ann. Intern. Med. 1993, 119, 1059-1066.
60. Fischer, A. R.; McFaddden, C. A.; Frantz, R.; Cohn, J.; Drazen, J. M.; Israel E. Chronic inhibition of 5-lipoxygenase decreases airway reactivity to cold, dry air independent of the acute inhibition of 5-lipoxygenase. Am. J. Respir. Crit. Care Med. 1994, 149, A1056.
61. Israel, E.; Cohn, J.; Dubé, L.; Drazen, J.; Group, Z. S. Reduction of steroid-rescue treatment for asthma by the 5-lipoxygenase inhibitor, zileuton. Asthma Theory Treat. (Chicago) 1995, A45.
62. Lauritsen, K.; Laursen, L. S.; Bukhave, K.; Rask-Madsen, J. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative 1986, 837-844.
63. K.; Laursen, L. S.; Lauritsen, K. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions 1992, C37-C45.
64. Peppercorn, M.; Das, K.; Elson, C.; Geraci, K.; Robinson, M.; Rubin, A.; Salzberg, B.; Wruble, L.; Dubé, L.; Rountree, L.; Broutman, L. Zileuton, a 5-lipoxygenase inhibitor, in the treatment of active ulcerative colitis: a double-blind placebo. Presented during Digestive Disease Week - American Gastroenterology Association, New Orleans, LA, 1994; A-558.
65. Hawkey, C.; Gasull, M.; Lauritsen, K.; Martin, F.; O'Morain, C.; Rask-Madsen, J.; Wright, J.; Dubé, L.; Rountree, L. Efficacy of zileuton, a 5-lipoxygenase inhibitor, in the maintenance of remission in patients with ulcerative colitis. Presented during Digestive Disease Week - American Gastroenterology Association, New Orleans, LA, 1994; A-559.
66. Braeckman, R. A.; Granneman, R.; Rubin, P. R.; Kesterson, J. W. Pharmacokinetics and metabolism of the new 5-lipoxygenase inhibitor A-64077 after single oral administration in man. J. Clin. Pharmacol. 1989, 29, 837.
67. Bell, R. L.; Brooks, D. W.; Young, P. R.; Lanni, C.; Stewart, A. O.; Bouska, J.; Malo, P. E.; Carter, G. W. A-78773: a selective, potent 5-lipoxygenase inhibitor. J. Lipid Mediators 1993, 6, 259-264.
68. Brooks, D. W.; Summers, J. B.; Stewart, A. O.; Bell, R. L.; Bouska. J.; Lanni, C.; Young, P. R.; Rubin, P.; Carter, G. W. Novel inhibitors of leukotriene biosynthesis. In Perspectives in Medicinal Chemistry; Testa, B., Kyburz, E., Fuhrer, W., Giger, R., Eds.; Verlag: Basel, 1993; Chapter 9, pp 119-134.
69. Bell R. L.; Bouska, J. B.; Malo, P. E.; Lanni, C.; Harris, R. R.; Otis, E. R.; Stewart, A. O.; Brooks, D. W.; Carter, G. W. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. J. Pharmacol. Exp. Ther. 1995, 272, 724-731.
70. Ojingwa, J. C.; Braeckman, R. A.; Hui, J.; Hansen, R. G.; Rubin, P. D. Pharmacokinetics and pharmacodynamics of the second-generation 5-lipoxygenase inhibitor A-78773 after single oral dosing in healthy volunteers. Pharm. Res. 1992, 9, (Suppl. 10), Abstract PPDM 8192.
71. Carter, G. W.; Bell, R. L.; Marsh, K.; Lanni, C.; Awni, W. M.; Bouska, J.; Stewart, A. O.; Hansen, R.; Dubé, L.; Brooks, D. W. Stereoseiective metabolism of the 5-lipoxygenase inhibitor A-78773. Ann. N. Y. Acad. Sci. 1994, 744, 262-272.
72. Brooks, C. D. W.; Stewart, A. O.; Basha, A.; Bhatia, P.; Ratajczyk, J. D.; Martin, J. G.; Craig, R. A.; Kolasa, T.; Bouska, J. B.; Lanni, C.; Harris, R. R.; Malo, P. E.; Carter, G. W.; Bell, R. L. (R)-(+)-N-[3-[5-(4-Fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N- hydroxyurea (ABT-761), a second generation 5-lipoxygenase inhibitor. J. Med. Chem. 1995, 38, 4768-4775.
73. Lehnigk, B.; Rabe, K. F.; Herst, R. S.; Carpentier, P. J.; Magnussen, H. Effect of ABT-761, a 5-lipoxygenase inhibitor, on exercise induced bronchoconstriction in patients with bronchial asthma. Am. J. Respir. Crit. Care Med. 1995, 151, A376.
74. VanSchoor, J.; Joos, G. F.; Kips, J. C.; Pauwels, R. A.; Drajesk, J. F.; Carpentier, P. J. The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatics. Am. J. Respir. Crit. Care Med. 1995, 151, A376.
75. Bird, T. G. C.; Bruneau, P.; Crawley, G. C.; Edwards, M. P.; Foster, S. J.; Girodeau, J.-M.; Kingston, J. F.; McMillan, R. M. (Methoxyalkyl)Thiazoles: A new series of potent, selective, and orally active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J. Med. Chem. 1991, 34, 2176-2186.
76. Crawley, G. C.; Dowell, R. I.; Edwards, P. N.; Foster, S. J.; McMillan, R. M.; Walker, E. R. H.; Waterson, D.; Bird, T. G. C.; Bruneau, P.; Girodeau, J.-M. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. J. Med. Chem. 1992, 35, 2600-2609.
77. Crawley, G. C.; Foster, S. J.; McMillan, R. M.; Walker, E. R. H. Discovery of ZD2138, a potent, selective, well-tolerated, nonredox inhibitor of the enzyme 5-lipoxygenase. In The Search for Anti-Inflammatory Drugs; Merluzzi, V. J., Adams, J., Eds.; Birkhauser: Boston, 1995; Chapter 7, pp 191-231.
78. Yates, R. A.; McMillan, R. M.; Ellis, S. H.; Hutchinson, M.; Culmore, E. M.; Wilkinson, D. M. A new non-redox 5-lipoxygenase inhibitor ICI D2138 is well tolerated and inhibits leukotriene synthesis in healthy volunteers. Am. Rev. Respir. Dis. 1992, 145, A745.
79. Nasser, S. M.; Bell, G. S.; Hawksworth, R. J.; Spruce, K. E.; McMillan, R.M.; Williams, A. J., Lee, T. H.; Arm, J. P. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax 1994, 49, 743-748.
80. Nasser, S. M.; Bell, G. S.; Foster, S. J.; Spruce, K.; McMillan, R M.; Williams, A. J.; Arm, J. P.; Lee, T. K. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994, 49, 749-756.
81. Strek, M. E.; Solway, J.; Saller, L.; Kowash, K.; Miller, C. J.; Israel, E. Effect of the 5-lipoxygenase inhibitor, ZD2138, on cold-air-induced bronchoconstriction in patients with asthma. Am. J. Respir. Crit. Care Med. 1995, 151, A377.
82. Zeneca tops Pounds 1 billion pharma Scrip 1995 2050 6-7
83. Ford-Hutchinson, A. W. Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions. Springer Semin. Immunopathol. 1993, 15, 37-50.
84. Young, R. N.; Gillard, J. W.; Hutchinson, J. H.; Leger, S.; Prasit, P. Discovery of inhibitors of the 5-lipoxygenase-activating protein (FLAP). J. Lipid Mediators 1993, 6, 233-238.
85. Vickers, P. J. 5-Lipoxygenase-activating protein (FLAP). J. Lipid Med. Cell Signalling 1995, 12, 185-194.
86. Wong, A.; Hwang, S. M.; Cook, M.; Hogaboom, G. K.; Crooke, S. T. Interactions of 5-lipoxygenase with membranes: Studies on the association of soluble enzyme with membranes and alterations in enzyme activity. Biochemistry 1988, 27, 6763-6769.
87. Rouser, C.; Kargman, S. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J. Biol. Chem. 1988, 263, 10980-10988.
88. Rouzer, C.; Ford-Hutchinson, A. W.; Morton, H. E.; Gillard, J. W. MK-886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenges leukocytes J. Biol. Chem. 1990, 265, 1436-1442.
89. Kargman, S.; Vickers, P. J.; Evans, J. F. A-23187-induced translocation of 5-lipoxygenase in osteosarcoma cells. J. Cell Biol. 1992, 119, 1701-1709.
90. Mancini, J. A.; Abramovitz, M.; Cox, M. E.; Wong, E.; Charleson, S.; Perrier, H.; Wang, Z.; Prasit, P.; Vickers, P. J. 5-Lipoxygenase-activating protein is an arachidonic acid binding protein. FEBS Lett. 1993, 318, 277-281.
91. Abramovitz, M.; Wong, E.; Cos, M. E.; Richardson, C. D.; Li, C.; Vickers, P. J. 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur. J. Biochem. 1993, 215, 105-111.
92. Hill, E.; Maclouf, J.; Murphy, R. C.; Henson, P. M. Reversible membrane association of neutrophil 5-lipoxygenase is accompanied by retention of activity and a change in substrate specificity. J. Biol. Chem. 1992, 267, 22048-22053.
93. Vickers, P. J.; O'Neill, G. P.; Mancini, J. A.; Charleson, S.; Abramovitz, M. Cross-species comparison of 5-lipoxygenase-activating protein. Mol. Pharmacol. 1992, 42, 1014-1019.
94. 2 to the nuclear fraction upon macrophage activation. Biochem. Bioahys. Res. Commun. 1993, 196, 147-153.
95. Woods, J. W.; Evans, J. F.; Ethier, D.; Scott, S.; Vickers, P. J.; Hearn, L.; Heibein, J. A.; Charleson, S.; Singer, I. I. 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J. Exp. Med. 1993, 178, 1935-1946.
96. Shen, T. Y.; Winter, C. A. Chemical and biological studies on indomethacin, sulindac and their analogs. In Advances in Drug Research; Harper, N. J., Simmonds, A. B., Eds.; Academic Press: New York, 1977.
97. Gillard, J. W.; Ford-Hutchinson, A. W.; Chan, C.; Charleson, S.; Denis, D.; Foster, A.; Fortin, R.; Léger, S.; McFarlane, C. S.; Morton, H.; Piechuta, H.; Riendeau, D.; Rouzer, C. A.; Rokach, J.; Young, R. N.; Maclntyre, D. E.; Peterson, L.; Bach, T.; Eiermann, G.; Hopple, S.; Humes, J.; Hupe, D.; Luell, S.; Metzger, J.; Meurer, R.; Miller, D. K.; Opas, E.; Pacholok, S. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-iso-propyfindol-2-yl]-2,2- dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 1989, 67, 456-464.
98. Bel, E. H.; Tanaka, W.; Spector, R.; Friedman, B.; Von de Veen, J. H.; Dijkman, J. H.; Sterk, P. J. MK-886, an effective oral leukotriene biosynthesis inhibitor on antigen-induced early and late asthmatic reactions in man. Am. Rev. Respir. Dis. 1990, 141, A31.
99. Charleson, S.; Prasit, P.; Léger, S.; Gillard, J. W.; Vickers, P.; Mancini, J. A.; Charleson, P.; Guay, J.; Ford-Hutchinson, A. W.; Evans, J. F. Characterization of a 5-lipoxygenase activating protein binding assay. Correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition. Mol. Pharamacol. 1992, 41, 873-379.
100. Musser J. H.; Chakraborty, U.; Sciortino, S.; Gordon, R. J.; Khandwala, A.; Neiss, E. S.; Pruss, T. P.; Van Inwegen, R.; Weinryb, I.; Coutts, S. M. Substituted arylmethyl phenyl ethers. Part 1. A novel series of 5-lipoxygenase inhibitor and leukotriene antagonists. J. Med. Chem. 1987, 30, 96-104.
101. Prasit, P.; Belley, M.; Evans, J. F.; Gauthier, J. Y.; Léveillé, C.; McFarlane, C. S.; MacIntyre, E.; Peterson, L.; Piechuta, H.; Therien, M.; Young, R. N.; Zamboni, R. A new class of leukotriene biosynthesis inhibitors: the development of ((4-(4-chlorophenyl)-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio) acetic acid, L-674,636. Bioorg. Med. Chem. Lett. 1991, 1, 645-648.
102. Prasit, P.; Vickers, P. J. Development of MK-0591: an orally leukotriene biosynthesis a novel mechanism of action In The Search for Anti-Inflammatory Drugs; Merluzzi, V. J., Adams, J., Eds.; Birkhauser: Boston, 1995; Chapter 8, pp 233-251.
103. Brideau, C.; Chan, C.; Denis, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Fortin, R.; Gillard, J. W.; Guay, J.; Hutchinson, J.; Jones, T.; Léger, S.; Mancini, J. A.; McFarlane, C. S.; Pickett, C.; Piechuta, H.; Prasit, P.; Riendeau, D.; Rouzer, C. A.; Tagari, P.; Vickers, P.; Young, R. N. Pharmacology of MK0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)indol-2-yl]-2,2- dimethyipropanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 1992, 70, 799-807.
104. Diamant, Z.; Timmers, M. C.; Van der Veen, H.; Friedman, B. S.; Smet, M. D.; Depré, M.; Hillard, D.; Bel, E. H.; Sterk, P. J. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J. Allergy Clin, Immunol. 1995, 95, 42-51.
105. Chapman, K. R.; Freidman, B. S.; Shingo, S.; Heyes, J.; Reiss, T.; Spectro, R. The efficacy of an oral inhibitor of leukotriene synthesis (MK-0591) in asthmatics treated with inhaled steroids. Am. J. Respir. Crit. Care Med. 1994, 149, A215.
106. Storms, W.; Friedman, B. S.; Zhang, J.; Santanello, N.; Allegar, N.; Appel, D.; Beaucher, W.; Bronsky, F.; Busse, W.; Chervinsky, P.; Dockhorn, R.; Edwards, T.; Goldstein, M.; Grossman, J.; Hendeles, L.; Kemp, J.; Memon, N.; Noonan, M.; Owens, G.; Shapiro, G.; Spirn, I.; Strek, M.; Stricker, W.; Tinkelman, D.; Townley, R.; Wanderer, A.; Winder, J.; Woehler, T. Treating asthma by blocking the lipoxygenase pathway. Am. J. Respir. Crit. Care Med. 1995, 151, A377.
107. Musser, J. H.; Kreft, A. F. Substituted-[2-quinolinyl(bridged)-aryfi compounds: modulators of eicosanoid biosynthesis and action. Drugs Future 1990, 15, 73-80.
108. Grimes, D.; Sturm, R. J.; Marinari, L. R.; Carlson, R. P.; Berkenkopf, J. W.; Musser, J. H.; Kreft, A. F.; Weichman, B. M. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity. Eur. J. Pharmacol, 1993, 236, 217-228.
109. Kreik A. F.; Marshali, L. A.; Wong, A. Structure-activity relationships in the quinoline-containing class of inhibitors of 5-lipoxygenase (5-LO) enzyme translocation and activation. Drugs Future 1994, 19, 255-264.
110. Wy-50295 Tromethamine. Drugs Future 1992, 17, 761-762.
111. Hatzelmann, A.; Fruchtmann, R.; Mohrs, K-H.; Raddatz, S.; Müller-Peddinghaus, R. Mode of action of new selective leukotriene biosynthesis inhibitor, BAY X1005 and structurally related compounds, Biochem. Pharmacol. 1993, 45, 101-111.
112. Fruchtmann, R.; Mohrs, K.-H.; Hatzelmann, A.; Raddatz, S.; Fugmann, B.; Junge, B.; Horstmann, H.; Müller-Peddinghaus, R. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions 1993, 38, 188-195.
113. Hatzelmann, A.; Goossens, J.; Fruchtmann, R.; Mohrs, K.-H.; Raddatz, S.; Müller-Peddinghaus, R. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system-implications for the function of 5-lipoxygenase activating protein. Biochem. Pharmacol. 1994, 47, 2259-2268.
114. Horstmann, R.; Beckermann, B.; Boettcher, M.; Dietrich, H.; Lemm, G.; Seitz, I.; Fauler, J. Clinical pharmacological investigations with the new leukotriene synthesis inhibitor BAY X1005. Am. J. Respir. Crit. Care Med. 1994, 149, A465.
115. Dahlén, S.-E.; Dahlén, B.; Ihre, E.; Kumlin, M.; Franzen, L.; Stensvad, F.; Larsson, C.; Bloomqvist, H.; Bjorck, T.; Zetterstrom, O. The leukotriene biosynthesis inhibitor BAY x1005 is a potent inhibitor of allergen-induced airway obstruction and leukotriene formation in man. Am. Rev. Respir. Dis. 1993, 147, A837.
116. O'Byrne, P. M.; Watson, R. M.; Strong, H. A.; Wyile, G. The effect of treatment with a 5-lipoxygenase inhibitor BAY x1005 on allergen-induced asthmatic responses in human subjects. Am. J. Respir. Crit. Care Med. 1994, 149, A532.
117. Fischer, A. R.; Drazen, J. M.; Roth, M.; Rosengerg, M. A.; Loper, M.; Jungerwirth, S.; Israel, E. The effect of a leukotriene synthesis inhibitor, BAY X1005, on bronchoconstriction induced by cold, dry air hyperventilation in asthmatics. Am. J. Respir. Crit. Care Med. 1994, 149, A1056.
118. Lichey, J.; Hummel, S.; Beck, E.; Ulbrich, E. Effects of leukotriene antagonist BAY x1005 versus placebo in patients with severe steroid dependent bronchial asthma. Am. J. Respir. Crit. Care Med. 1995, 151, A377.
119. Virchow, J. C.; Noller, P. S.; Wiebmann, K. J.; Buhl, R.; Thalhofer, S.; Dorow, G.; Kunkel, G.; Ukena, D.; Ulbrich, E.; Sybrecht, G.; Matthys, H. Multicenter trial of BAY x1005, a new 5-lipoxygenase activating protein (FLAP) inhibitor in the treatment of chronic asthma. Am. J. Respir. Crit. Care Med. 1995, 151, A377.
120. Meltzer, S. S.; Johns, M. A.; Rechsteiner, E. A.; Jungerwirth, S.; D'Amico, J. M.; Bleeker, E. R. Bronchodilatory effects of BAY x1005, a 5-lipoxygenase inhibitor, in mild to moderate asthma. J. Allergy Clin. Immunol. 1994, 93, A792.
121. Matzke, M.; Beckermann, B.; Fruchtmann, R.; Fugmann, B.; Gardiner, P. J.; Goossens, J.; Hatzelmann, A.; Junge, B.; Keldenich, J.; Konlsdorfer, C.; Mohrs, K.-H.; Müller-Peddinghaus, R.; Raddatz, S. Leukotriene synthesis inhibitors of the quinoline type: parameters for the optimization of efficacy. Eur. J. Med. Chem. 1995, 30, 442s-443s.
122. Appleton, R. A.; Bantick, J. R.; Chamberlain, T. R.; Hardern, D. N.; Lee, T. B.; Pratt, A. D. Antagonists of slow reacting substance of anaphylaxis. Synthesis of a series of chromone-2-carboxylic acids. J. Med. Chem. 1977, 20, 371-379.
123. Ford-Hutchinson, A.; Young, R.; Gillard, J. Leukotriene blockers, novel therapeutic strategies for the treatment of asthma. Drug. News Perspect. 1991, 4, 264-271.
124. von Sprecher, A.; Beck, A.; Gerspacher, M.; Bray, M. A. Peptidoleukotriene antagonists: State of the art. Chimia 1992, 46, 304.
125. 4 receptor antagonists: A new approach to antiasthma drug therapy. Drug News Perspect. 1989, 2, 202-213.
126. 4 with special emphasis on CGP 45715A. Drugs Future 1991, 16, 827-843.
127. 4 antagonist L-649,923 on the response to inhaled antigen in asthma. J. Allergy Clin. Immunol. 1987, 79, 811-816.
128. Rasmussen, J. B.; Eriksson, L. O.; Tagari, P.; Stahl, E. G.; Andersson, K. E. Reduced nonspecific bronchial reactivity and decreased airway response to antigen challenge in atopic asthmatic patients treated with the inhaled leukotriene D4 antagonist, L-648,051. Allergy 1992, 47, 604-609.
129. Rasmussen, J. B.; Eriksson, L. O.; Andersson, K. E. Reversal and prevention of airway response to antigen challenge by the inhaled leukotriene D4 antagonist (L-648,051) in patients with atopic asthma. Allergy 1991, 46, 266-273.
130. Shaker, G.; Glowvsky, M. M.; Kebo, D.; Glovsky, S.; Dowell, A. Reversal of exercise induced asthma by the LTD4, LTE4 antagonists LY 171883. J. Allergy Clin. Immunol. 1988, 81, 315.
131. Israel, E.; Juniper, E. F.; Callaghan, J. T.; Mathur, P. N.; Morris, M. M.; Dowell, A. R.; Enas, G. G.; Hargreave, F. E.; Drazen, J. M. Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics. Am. Rev. Respir. Dis. 1989, 140, 1348-1353.
132. Fuller, R. W.; Black, P. N.; Dollery, C. T. Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects. J. Allergy Clin. Immunol. 1989, 83, 939-944.
133. Cloud, M. L.; Enas, G. C.; Kemp, J.; Platts-Mills, T.; Altman, L. C.; Townley, R.; Tinkelman, D.; King, T., Jr.; Middleton, E.; Sheffer, A. L.; et al. A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am. Rev. Respir. Dis. 1989, 140, 1336-1339.
134. Fleisch, J. H.; Rinkema, L. E.; Haisch, K. D.; Swanson-Bean, D.; Goodson, T.; Ho, P. P.; Marshall, W. S. LY171883, 1-(2-hydroxy-3-propyl-4-) 4-(1H-tetrazol-5-yl) butoxy greater than phenyl greater than ethanone, an orally active leukotriene D4 antagonist. J. Pharmacol. Exp. Ther. 1985, 233, 148-157.
135. Bendele, A. M.; Hoover, D. M.; van Lier, R. B.; Foxworthy, P. S.; Eacho, P. I. Effects of chronic treatment with the leukotriene D4-antagonist compound LY171883 on B6C3F1 mice. Fundam. Appl. Toxicol. 1990, 15, 676-682.
136. Fleisch, J. H.; Cloud, M. L.; Marshall, W. S. A brief review of preclinical and clinical studies with LY171883 and some comments on newer cysteinyl leukotriene receptor antagoniste. Ann. N. Y. Acad. Sci. 1988, 524, 356-368.
137. Gleason, J. G.; Hall, R. F.; Perchonock, C. D.; Erhard, K. F.; Frazee, J. S.; Ku, T. W.; Kondrad, K.; McCarthy, M. E.; Mong, S.; Crooke, S. T.; Chi-Russo, G.; Wasserman, M. A.; Torphy, T. J.; Muccitelli, R. M.; Hay, D. W.; Tucker, S. S.; Vickery-Clark, L. High-affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl] propanoic acid. J. Med. Chem. 1987, 30, 959-961.
138. Torphy, T. J.; Faiferman, I.; Gleason, J. G.; Hall, R. F.; Lewis, M. A.; Broom, C.; Helfrich, H. M.; Newton, J. F.; Hay, D. W. The preclinical and clinical pharmacology of SK&F 104353, a potent and selective peptidoleukotriene receptor antagonist. Ann. N. Y. Acad. Sci. 1991, 629, 157-167.
139. Robuschi, M.; Fuccella, L. M.; Riva, E.; Vida, E.; Barnabe, R.; Rossi, M.; Gambaro, G.; Spagnotto, S.; Bianco, S. Prevention of exercise-induced bronchoconstriction by a leukotriene antagonist SKF-104353. A double blind study vs disodium cromoglycate DSCG and placebo. International Conference of the American Lung Association and the American Thoracic Society, Anaheim, California, 1991; A642.
140. Abram, T. S.; Boeshagen, H.; Butler, J. E.; Cuthbert, N. J.; H. P.; Gardiner P. J.; Hartwig, W.; Kluender, H. C.; Norman, P.; Meier H.; Rosentreter, U.; Schlemmer, K. H.; Tudhope, S. R.; Taylor, W. A. A New structural analogue antagonist of peptido-ieukotrienes the discovery of Bay x7195. Bioorg. Med. Chem. Lett. 1993, 3, 1993.
141. Wensing, G.; Heinig, R.; Kuhlman, J. Effect of the leukotriene D4 (LTD4)-receptor antagonist Bay x 7195 on LTD4-induced bronchoconstriction in normal subjects. Clin. Pharmacol. Ther. 1994, 55, 203.
142. Wisniewski, P. L.; Busse, W. W.; Meltzer, S. S.; WIlliams, J.; Shannon, T.; Sorkness, C.; Bleecker, E. R. Bronchodilatory effects of BAY-x7195, a selective leukotriene receptor antagonist. J. Allergy Clin. Immunol. 1995, 95, 300.
143. Fish, J. E.; Gillen, M. S.; Smith, J. A. The Effect of the oral Leukotriene D-4 LTD-4 antagonist RG 12525 on ragweed antigen induced bronchospasm. J. Allergy Clin. Immunol. 1992, 89, 236.
144. Welch, M. J.; Nelson, H. S.; Paull, B. R.; Smith, J. A.; Feiss, G.; Tobey, R. E. Effect of RG 12525, a new leukotriene antagonist, on pulmonary function of asthmatic adults. Ann. Allergy 1994, 72, 348-352.
145. Wahedna, I.; Wisniewski, A. F. Z.; Wong, C. S.; Tattersfield, A. E. Effect of multiple doses of RG 12525 an oral leukotriene D-4 antagonist in chronic asthma. Am. Rev. Respir. Dis. 1992, 145.
146. Zamboni, R.; Belley, M.; Champion, E.; Charette, L.; DeHaven, R.; Frenette, R.; Gauthier, J. Y.; Jones, T. R.; Leger, S.; Masson, P.; McFarlane, C. S.; Metters, K.; Pong, S. S.; Piechuta, H.; Rokach, J.; Thérien, M.; Williams, H. W. R.; Young, R. N. Development of a novel series of styrylquinoline compounds as high-affinity leukotriene D4 receptor antagonists: synthetic and structure-activity studies leading to the discovery of (+-)-3-[[[3-[2-(7-chioro-2-quinolinyl)-(E)-ethenyl]phenyl][[3-(dimethylaimno)-3- oxopropyl]thio]methyl]thio]propionic acid. J. Med. Chem. 1992, 35, 3832-3844.
147. Kips, J. C.; Joos, G. F.; De Lepeleire, I.; Margolskee, D. J.; Buntinx, A.; Pauwels, R. A.; Van der Straeten, M. E. MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human. Am. Rev. Respir. Dis. 1991, 144, 617-621.
148. Rasmussen, J. B.; Eriksson, L. O.; Margolskee, D. J.; Tagari, P.; Williams, V. C.; Andersson, K. E. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J. Allergy Clin. Immunol. 1992, 90, 193-201.
149. 4 receptor antagonist. J, Allergy Clin. Immunol. 1990, 85, 197A.
150. Manning, P. J.; Watson, R. M.; Margolskee, D. J.; Williams, V. C.; Schwartz, J. I.; O'Byrne, P. M. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N. Engl. J. Med. 1990, 323, 1736-1739.
151. Gaddy, J. N.; Margolskee, D. J.; Bush, R. K.; Williams, V. C.; Busse, W. W. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am. Rev. Respir. Dis. 1992, 146, 358-363.
152. 4 antagonists (MK-571) significantly reduces airway obstruction in mild to moderate asthma. J. Allergy Clin. Immunol. 1991, 87, 308.
153. Joos, G. F.; Kips, J. C.; Pauwels, R. A.; Van der Straeten, M. E. The effect of aerosolized SK&F104353-Z2 on the bronchocon-strictor effect of leukotriene D4 in asthmatics. Pulm. Pharmacol. 1991, 4, 37-42.
154. 4 receptor antagonist in patients with chronic asthma. J. Clin. Allergy Immunol. 1991, 87, 309.
155. Grossman, S. J.; DeLuca, J. G.; Zamboni, R. J.; Keenan, K. P.; Patrick, D. H.; Herold, E. G.; van Zwieten, M. J.; Zacchei, A. G. Enantioselective induction of peroxisomal proliferation in CD-1 mice by leukotriene antagonists. Toxicol. Appl. Pharmacol. 1992, 116, 217-224.
156. Impens, N.; Reiss, T. F.; Teahan, J. A.; Desmet, M.; Rossing, T. H.; Shingo, S.; Zhang, J.; Schandevyl, W.; Verbesselt, R.; Dupont, A. G. Acute bronchodilation with an intravenously administered leukotriene D4 antagonist, MK-679. Am. Rev. Respir. Dis. 1993, 147, 1442-1446.
157. Lammers, J. W.; Van Daele, P.; Van den Elshout, F. M.; Decramer, M.; Buntinx, A.; De Lepeleire, I.; Friedman, B. Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukast-MK-0679) in asthmatic patients. Pulm. Pharmacol. 1992, 5, 121-125.
158. Dahlen, B.; Kumlin, M.; Margolskee, D. J.; Larsson, C.; Blomqvist, H.; Williams, V. C.; Zetterstrom, O.; Dahlen, S. E. The leukotriene-receptor antagonist MK-0679 blocks airway abstruction induced by inhaled, lysine-aspirin in asthmatics. Eur. Respir. J. 1993, 6, 1018-1026
159. Dahlen, B.; Margolskee, D. J.; Zetterstrom, O.; Dahlen, S. E. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993, 48, 1205-1210.
160. Ford-Hutchinson, A. W. Leukotrienes antagonists and biosynthesis inhibitors: Novel therapies for the treatment of human bronchial asthma and other diseases. Ninth International Conference on Prostaglandins and Related Compounds, Florence, Italy, 1994; 3.
161. 4 receptor antagonist devoid of peroxisomal enzyme induction. Bioorg. Med. Chem. Lett. 1995, 5, 283-288
162. 4 receptor antagonism in the airways of asthmatics. Am. J. Respir. Crit. Care Med. 1994, 149, A465.
163. 4 antagonist (MK-476). Am. J. Respir. Crit. Care Med. 1994, 149, A216.
164. 4 receptor antagonist, inhibits exercise induced bronchoconstriction in asthmatics at the end of a once daily dosing interval. Am. J. Respir. Crit. Care Med. 1995, 151, A377.
165. 4 receptor antagonist, improves the signs and symptoms of asthma with a dose as low as 10 mg, once daily. Am. J. Respir. Crit. Care Med. 1995, 151, A378.
166. ONO-1078. Drugs Future 1988, 13, 317-320.
167. 4 challenge in normal male subjects. Am. J. Respir. Crit. Care Med. 1995, 151, A378.
168. Taniguchi, Y.; Tamura, G.; Honma, M.; Aizawa, T.; Maruyama, N.; Shirato, K.; Takishima, T. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J. Allergy Clin. Immunol. 1993, 92, 507-512.
169. Fujimura, M.; Sakamoto, S.; Kamio, Y.; Matsuda, T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperrespon-siveness in patients with asthma. Respir. Med. 1993, 87, 133-138.
170. Yamamoto, H.; Nagata, M.; Kuramitsu, K.; Tabe, K.; Kiuchi, H.; Sakamoto, Y.; Yamamoto, K.; Dohi, Y. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am. J. Respir. Crit. Care Med. 1994, 150, 254-257.
171. Barnes, N. C.; Pujet, J.-C. First clinical experience with the oral leukotriene receptor antagonist, pranlukast in northern European patients with mild to moderate asthma. Am. J. Respir. Crit. Care Med. 1995, 151, A378.
172. Grossman, J.; Bronsky, E.; Busse, W.; Montanaro, A.; Southern, L.; Tinkelman, D.; Dubb, J.; Faiferman, I. A multicentere, double-blind, placebo controlled study to evaluate the safety tolerability and clinical activity of oral twice daily LTA, pranlukast in patients with mild to moderate asthma. J. Allergy Clin, Immunol. 1995, 95, 352.
173. Brown, F. J. Discovery of accolate™ (ICI 204,219) a peptide leukotriene antagonist for asthma. In The Search for Anti-Inflammatory Drugs; Merluzzi, V. J., Adams, J., Eds.; Birkhauser: Boston, 1995; Chapter 6, pp 161-189.
174. Krell, R. D.; Aharony, D.; Buckner, C. K.; Keith, R. A.; Kusner, E. J.; Snyder, D. W.; Bernstein, P. R.; Matassa, V. G.; Yee, Y. K.; Brown, F. J.; et al. The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist. Am. Rev. Respir. Dis. 1990, 141, 978-987.
175. Smith, L. J.; Geller, S.; Ebright, L.; Glass, M.; Thyrum, P. T. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am. Rev. Respir. Dis. 1990, 141, 988-992.
176. Nathan, R. A.; Glass, M.; Minkwitz, M. C. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 1994, 105, 483-488.
177. O'Shaughnessy, K. M.; Taylor, I. K.; O'Connor, B.; O'Connell, F.; Thomson, H.; Dollery, C. T. Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchocon-striction. Am. Rev. Respir. Dis. 1993, 147, 1431-1435.
178. Findlay, S. R.; Barden, J. M.; Easley, C. B.; Glass, M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J. Allergy Clin. Immunol. 1992, 89, 1040-1045.
179. Hui, K. P.; Barnes, N. C. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991, 337, 1062-1063.
180. 4 receptor antagonist in subjects with bronchial asthma. Am. J. Respir. Crit. Care Med. 1995, 150, 618-623.
181. Lockey, R. F.; Lavins, B. J.; Snader, L. Thirteen weeks of treatment with zafirlukast (Accolate™) in patients with mild to moderate asthma. J. Allergy Clin. Immunol. 1995, 95, 350.
182. Nathan, R. A.; Glass, M.; Snader, L. Thirteen weeks of treatment with zafirlukast (Accolate™) or cromolyn sodium (Intal™) in patients with mild or moderate asthma. J. Allergy Clin. Immunol. 1995, 95, 350.
183. 4-receptor antagonist, ICI 204,219 relieves symptoms of acute seasonal allergic rhinitis. Am. J. Respir. Crit. Care Med. 1995, 151, 1734-1739.
184. 4 antagonists. Curr. Opin. Invest. Drugs 1994, 3, 13-22.
185. 4 receptor antagonists - A most discriminating class of antiinflammatory agent? Drugs Future 1992, 17, 819-830.
186. Sawyer, J. S. Leukotriene B4 Antagonists. Expert Opin. Invest. Drugs 1996, 5, 73-77.
187. 4 receptor antagonist. J. Pharmacol. Exp. Ther. 1994, 268, 1499-1505.
188. Fretland, D. J.; Widomski, D.; Tsai, B. S.; Zemaitis, J. M.; Levin, S.; Djuric, S. W.; Shone, R. L.; Gaginella, T. S. Effect of the leukotriene B4 receptor antagonist SC-41930 on colonic inflammation in rat, guinea pig and rabbit. J. Pharmacol. Exp. Ther. 1990, 255, 573-576.
189. Fretland, D. J.; Levin, S.; Tsai, B.; Djuric, S. W.; Widomski, D. L.; Zemaitis, J. M.; Shone, R. L.; Bauer, R. F. The effect of leukotriene-B4 receptor antagonist, SC-41930, on acetic acid-induced colonic inflammation. Agents Actions 1989, 27, 395-397.
190. Clapp, N.; Henke, M.; Hansard, R.; Carson, R.; Walsh, R.; Widomski, D.; Anglin, C.; Fretland, D. Inflammatory mediator changes in cotton-top tamarins after SC-41930 anti-colitic therapy. Agents Actions 1993, 39, C8-10.
191. 4 production in ulcerative colitis effects of three potentially efficacious new agents (SC45662, SC461930, Misoprostol). Gastroenterology 1990, 98, A450.
192. 4 receptor antagonist SC-41930. J. Pharmacol. Exp. Ther. 1992, 260, 187-191.
193. 4 receptor antagonist with high intrinsic potency and selectivity. Bioorg. Med. Chem. Lett. 1994, 4, 811-816.
194. Yu, S. S.; Djuric, S. W.; Dygos, J. H.; Tsai, B. S.; Paulson, S. K.; Smith, P. F.; Fretland, D. J. SC-53228. Drugs Future 1994, 19, 1093-1097.
195. 4 receptor antagonist. Inflamm. Res. 1995, 44, S143-S144.
196. 4 receptor antagonist, SC-53228. Inflammation 1995, 19, 503-515.
197. 4 receptor antagonist, SC 53228. Inflammation 1995, 19, 193-205.
198. 4 from leukocyte membrane preparations by 12R- and 12S-HETE. Biochim. Biophys. Acta 1987, 917, 406-410.
199. 4-receptor antagonist, ICI 204,219 relieves symptoms of acute seasonal allergic rhinitis. Am. J. Respir. Crit. Care Med. 1995, 151, 1734-1739.
200. 4-receptor antagonist, ICI 204,219 relieves symptoms of acute seasonal allergic rhinitis. Am. J. Respir. Crit. Care Med. 1995, 151, 1734-1739.
201. 4 Antagonists as Potential Therapeutic Agents, New York, 1994.
202. 4 receptor antagonists: The LY255283 series of hydroxyacetophenones. J. Med. Chem. 1992, 35, 1818-1828.
203. 4) Receptor Antagonists: A Series of (Hydroxyphenyl)pyrazoles. J. Med. Chem. 1994, 37, 2411-2420.
204. 4-receptor antagonist in endotoxin shock: A prospective, controlled trial in a porcine model. Crit. Care Med. 1993, 21, 1825-1837.
205. 4 receptor antagonist, limits activation of neutrophils and prevents acute lung injury induced by endotoxin in pigs. Surgery 1993, 114, 191-198.
206. 4 receptor antagonist. Eur. J. Pharmacol. 1992, 223, 57-64.
207. DeLong, A. F.; Oldham, S. W.; Wiltse, C. G.; Epinette, W. W.; McDonald, C. J.; Callaghan, J. T. HPLC assay of LY223982 in plasma and urine during phase I safety and topical activity evaluation in psoriasis. Pharmacologist 1991, 33, 497.
208. 4 receptor antagonists. Bioorg. Med. Chem. Lett. 1993, 3, 1981-1984.
209. 4 receptor antagonists. J. Med. Chem. 1993, 36, 3982-3984.
210. 4 receptor antagonists. Bioorg. Med. Chem. Lett. 1992, 2, 1669-1674.
211. 4 receptor antagonism. Bioorg. Med. Chem. Lett. 1993, 3, 1147-1152.
212. 4. Bioorg. Med. Chem. Lett. 1993, 3, 1985-1990.
213. Sawyer, J. S.; Bach, N. J.; Baker, S. R.; Baldwin, R. F.; Borromeo, P. S.; Cockerham, S. L.; Fleisch, J. H.; Floreancig, P.; Froelich, L. L.; Jackson, W. T.; Marder, P.; Palkowitz, J. A.; Roman, C. R.; Saussy, D. L.; Schmittling, E. A.; Silbaugh, S. A.; Spaethe, S. M.; Stengel, P. W.; Sofia, M. J. Synthetic and structure-activity studies on acid-substituted 2-arylphenols: Discovery of 2-(2-propyl-3-(3-(2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy)-propoxy)phenoxy) benzoic acid, a high-affinity leukotriene B-4 receptor antagonist. J. Med. Chem. 1995, 38, 4411-4432.
214. 4 receptor antagonist. Biochem. Phamacol. 1995, 49, 1683-1690.
215. 4 induced neutrophil functions. Prostaglandins 1992, 44, 261-275.
216. 4 in humans. Adv. Prostaglandin Thromboxane Res. 1995, 23, 279-281.
217. 4 receptor antagonist. J. Med. Chem. 1993, 36, 2703-2705.
218. 4 receptor antagonist demonstrating potent antiinflammatory activity. Adv. Prostaglandin Thromboxane Res. 1995, 23, 275-277.
219. 4 antagonist with oral activity in the murine collagen induced arthritis model. J. Med. Chem. 1994, 37, 3197-3199.
220. 4 receptor antagonist CP-105696. J. Pharmacol. Exper. Ther. 1995, 273, 176-184.
221. 4 antagonist CP 105,696. 7th International Conference of the Inflammation Research Association, White Haven, PA, 1994; P26.
222. 4 stimulated CD11β upregulation in vitro and ex vivo. 7th International Conference of the Inflammation Research Association, White Haven, PA, 1994; W23.
223. 4 antagonist, CP-105696. 7th International Conference of the Inflammation Research Association, White Haven, PA, 1994; W6.
224. 4 antagonists. 7th International Conference of the Inflammation Research Association, White Haven, PA, 1994; P29.
225. 4 antagonists in the mouse ear edema and rat neutropenia models. Inflamm. Res. 1995, 44, S141-S142.
226. 4 Antagonists as Potential Therapeutic Agents, New York, 1994.
227. 4 induced CD11/β expression. Clin. Pharmacol. Ther. 1994, 55, 199.
228. 4 induced CD11b expression. Clin. Pharmacol. Ther. 1995, 57, 153.
229. Serhan, C. N.; Hamberg, M.; Samuelsson, B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 5335.
230. Stenke, L.; Reizenstein, P.; Lindgren, J. A. Leukotriene and Lipoxins - new potential performers in the regulation of human myelopoiesis. Leukotriene Res. 1994, 18, 727-732.
231. Labat, C.; Ortiz, J. L.; Norel, X.; Gorenne, I.; Verley, J.; Abram, T. S.; Cuthbert, N. J.; Tudhope, S. R.; Norman, P.; Gardiner, P.; Brink, C. A second cysteinyl leukotriene receptor in human lung. J. Pharmacol. Exp. Ther. 1992, 263, 800-805.
232. 4 hydrolase. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 6671-6681.
233. 4 hydrolase. Curr. Opin. Invest. Drugs 1993, 2, 1037-1039.
234. 4 hydrolase. Bioorg. Med. Chem. Lett. 1995, 5, 2517-2522.
235. 4 synthase. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11603-11606.
236. 4. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 7663-7667.
237. 4 synthase. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9745-9749.
238. 4 synthase. Int. Arch. Allergy Immunol. 1995, 107, 19-24.
239. 4 synthase. J. Lipid Med. Cell Signalling 1995, 12, 333-341.
240. 4 synthase. J. Med. Chem. 1995, 38, 4538-4547.
241. Young, P. R.; Bell, R. L.; Lanni, C.; Summers, J. B.; Brooks, D. W.; Carter, G. W. Inhibition of leukotriene biosynthesis in the rat peritoneal cavity. Eur. J. Pharamcol. 1991, 205, 259-266.
242. Malo, P. E.; Shaughnessy, T. K.; Bell, R. L.; Bouska, J.; Hinz, W.; Majest, S.; Summers, J. B.; Brooks, D. W.; Carter, G. W. The effect of 5-lipoxygenase inhibition on arachidonic acid induced (AAI) bronchoconstriction in the anesthetized guinea pig. Pharmacologist 1989, 31, A291.
243. Malo, P. E.; Bell, R. L.; Shaughnessy, T. K.; Summers, J. B.; Brooks, D. W.; Carter, G. W. The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis. Pulm. Pharmacol. 1994, 7, 73-79.
244. Tateson, J. E.; Randall, R. W.; Reynolds, C. H.; Jackson, W. P.; Bhattacherjee, P.; Salmon, J. A.; Garland, L. G. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br. J. Pharmacol. 1988, 94, 528-539.
245. Payne, A. N.; Garland, L. G.; Lees, I. W.; Salmon, J. A. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects on bronchial anaphylaxis in anaesthetized guinea-pigs. Br. J. Pharmacol. 1988, 94, 540-546.
246. Higgs, G. A.; Follenfant, R. L.; Garland, L. G. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects of acute inflammatory responses. Br. J. Pharmacol. 1988, 94, 547-551.
247. McMillan, R. M.; Spruce, K. E.; Crawley, G. C.; Walker, E. R. H.; Foster, S. J, Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase. Br. J. Pharmacol. 1992, 107, 1042-1047.
248. Depre, M.; Friedman, B.; Tanaka, W.; Van, H. A.; Buntinx, A.; DeSchepper, P. J. Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans. Clin. Pharmacol. Ther. 1993, 53, 602-607.
249. Friedman, B. S.; Bel, E. H.; Buntinx, A.; Tanaka, W.; Han, Y. H.; Shingo, S.; Spector, R.; Sterk, P. Oral Leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am. Rev. Respir. Dis. 1993, 147, 839-844.
250. Depré, M.; Freidman, B.; Hecken, A. V.; DeLepeleire, I.; Tanaka, W.; Dallob, A.; Shingo, S.; Porras, A.; Lin, C.; DeSchepper, P. J. Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor. Clin. Pharmacol. Ther. 1994, 56, 22-30.
251. Müller-Peddinghaus, R.; Kohlsdorfer, C.; Theisen-Popp, P.; Fruchtmann, R.; Perzborn, E.; Beckermann, B.; Bühner, K.; Ahr, H.-J.; Mohrs, K.-H. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J. Pharmacol. Exp. Ther. 1993, 267, 51-57.
252. Gardiner, P. J.; Cuthbert, N. J.; Francis, H. P.; Fritzgerald, M. F.; Thompson, A. M.; Carpenter, T. G.; Patel, U. P.; Newton, B. B.; Mohrs, K.; Müller-Peddinghaus, R.; Taylor, W. A. Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005. Eur. J. Pharmacol. 1994, 258, 95-102.
253. Taylor, I. K.; O'Shaughnessy, K. M.; Fuller, R. W.; Dollery, C. T. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991, 337, 690-694.
254. Dahlen, B.; Zetterstrom, O.; Bjorck, T.; Dahlen, S. E. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur. Respir. J. 1994, 7, 324-331.
255. Finnerty, J. P.; Wood-Baker, R.; Thomson, H.; Holgate, S. T. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am. Rev. Respir. Dis. 1992, 145, 746-749.
256. Makker, H. K.; Lau, L. C.; Thomson, H. W.; Binks, S. M.; Holgate, S. T. The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am. Rev. Respir. Dis. 1993, 147, 1413-1418.
257. 4 receptor antagonist, ICI 204,219 on cold-air-induced bronchoconstriction in patients with asthma. J. Allergy Clin. Immunol. 1994, 93, 295.
258. Kidney, J. C.; Ridge, S. M.; Chung, K. F.; Barnes, P. J. Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219. Am. Rev. Respir. Dis. 1993, 147, 215-217.
259. Chu, S. S. REV-5901A. Drugs Future 1987, 12, 1025-1028.
260. 4 induced bronchoconstriction in man. Br. J. Clin. Pharmacol. 1988, 25, 111P-112P.
261. Cohen, N.; Weber, G.; Banner, B. L.; Lopresti, R. J.; Schaer, B.; Focella, A.; Zenchoff, G. B.; Chiu, A. M.; Todaro, L.; O'Donnell, M.; Welton, A. F.; Brown, D.; Garippa, R.; Crowley, H.; Morgan, D. W. 3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists. J. Med. Chem. 1989, 32, 1842-1860.
262. Holroyde, M. C.; Cole, M.; Altounyan, R. E. C.; Dixon, M.; Elliott, E. V. Bronchoconstriction produced in man by leukotrienes C and D. Lancet 1981, 2, 17-18.
263. Lee, T. H.; Walport, M. J.; Wilkinson, A. H.; Turner-Warwick, M.; Kay, A. B. Slow-reacting substance of anaphylaxis antagonist FPL 55712 in chronic asthma. Lancet 1981, 2, 304-305.
264. Jones, T. R.; Young, R.; Champion, E.; Charette, L.; Denis, D.; Ford-Hutchinson, A. W.; Frenette, R.; Gauthier, J. Y.; Guindon, Y.; Kakushima, M.; et al. L-649,923, sodium (beta S*, gamma R*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylthio)-gamma-hydroxy- beta-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonist. Can. J. Physiol. Pharmacol. 1986, 64, 1068-1075.
265. Barnes, N.; Piper, P. J.; Costello, J. The effect of an oral leukotriene antagonist L-649,923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. J. Allergy Clin. Immunol. 1987, 79, 816-821.
266. 4 antagonists. Drugs Future 1988, 13, 745.
267. Jones, T. R.; Guindon, Y.; Champion, E.; Charette, L.; DeHaven, R. N.; Denis, D.; Ethier, D.; Ford-Hutchinson, A. W.; Fortin, R.; Frenette, R.; et al. L-648,051: an aerosol active leukotriene D4 receptor antagonist. Adv. Prostaglandin Thromboxane Res. 1987, 17B, 1012-1017.
268. Evans, J. M.; Barnes, N. C.; Zakrzewski, J. T.; Sciberras, D. G.; Stahl, E. G.; Piper, P. J.; Costello, J. F. L-648,051, a novel cysteinyl-leukotriene antagonist is active by the inhaled route in man. Br. J. Clin. Pharmacol. 1989, 28, 125-135.
269. Bel, E. H.; Timmers, M. C.; Dijkman, J. H.; Stahl, E. G.; Sterk, P. J. The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J. Allergy Clin. Immunol. 1990, 85, 1067-1075.
270. Aharony, D.; Falcone, R. C.; Krell, R. D. Inhibition of 3H-leukotriene D4 binding to guinea pig lung receptors by the novel leukotriene antagonist ICI 198,615. J. Pharmacol. Exp. Ther. 1987, 243, 921-926.
271. Gapinski, D. M.; Roman, C. R.; Rinkema, L. E.; Fleisch, J. H. Leukotriene receptor antagonists. 4. Synthesis and leukotriene D4/E4 receptor antagonist activity of 4-(alkyl)acetophenone derivatives. J. Med. Chem. 1988, 31, 172-175.
272. 4 induced bronchoconstriction by p.o. administration of LY-171883 in nonasthmatic subjects. J. Pharmacol. Exp. Ther. 1988, 246, 732-738.
273. Hay, D. W. P.; Newton, J. F.; Torphy, T. J.; Gleason, J. G. SKF 104353. Drugs Future 1990, 15, 240.
274. Evans, J. M.; Piper, P. J.; Costello, J. F. The pharmacological profile of SK&F 104353-Z2, a potent, selective inhaled antagonist of cysteinyl leukotrienes, in normal man. Adv. Prostaglandin Thromboxane Res. 1991, 21A, 469-472.
275. Christie, P. E.; Smith, C. M.; Lee, T. H. The potent and selective sulfidopeptide leukotriene antagonsit, SK&F 104353, inhibits aspirin-induced asthma. Am. Rev. Respir. Dis. 1991, 144, 957-958.
276. Boot, J. R.; Bond, A.; Gooderham, R.; O'Brien, A.; Parsons, M.; Thomas, K. H. The pharmacological evaluation of LY 170680, a novel leukotriene D4 and E4 antagonist in the guinea-pig. Br. J. Pharmacol. 1989, 98, 259-267.
277. Wood-Baker, R.; Phillips, G. D.; Luca, R. A.; Turner, G. A.; Holgate, S. T. The effect of inhaled LY-170680 on leukotriene-D4 Induced bronchoconstriction in healthy volunteers. Drug Invest. 1991, 3, 239-247.
278. Baker, S. R.; Boot, J. R.; Lucas, R.; Wishar, G. Sulukast. Drugs Future 1991, 16, 432.
279. Hay, D. W.; Muccitelli, R. M.; Vickery-Clark, L. M.; Novak, L. S.; Osborn, R. R.; Gleason, J. G.; Yodis, L. A.; Saverino, C. M.; Eckardt, R. D.; Sarau, H. M.; Wasserman, M. A.; Torphyt, T. J.; Newton, J. F. Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig. Pulm. Pharmacol. 1991, 4, 177-189.
280. Mansell, L. J.; Evans, J.; Yeulet, S.; Moore, N.; Laroche, J.; Barrow, S. Effects of SKF 106203-z-2 on leukotriene induced bronchoconstriction in healthy male volunteers. Pharm. Res. 1991, 8, S249.
281. Musser, J. H.; Kreft, A. F.; Bender, R. H.; Kubrak, D. M.; Carlson, R. P.; Chang, J.; Hand, J. M. N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl]sulfonamides: potent orally active leukotriene D4 antagonists of novel structure. J. Med. Chem. 1989, 32, 1176-1183.
282. Leukotriene research making progress. Scrip 1991, 1613, 26.
283. Ahnfelt-Rønne, I.; Kirstein, D.; Kaergaard-Nielsen, C. A novel leukotriene D4/E4 antagonist, SR2640 (2-[3-(2-quinolylmethoxy)-phenylamino]benzoic acid). Eur. J. Pharmacol. 1988, 155, 117-128.
284. Frølund, L.; Madsen, F.; Nielsen, J.; Nielsen, O. H.; Ahnfelt-Rønne, I.; Thomsen, M. K.; Kissmeyer, A. M.; Langholz, E. Reproducibility of leukotriene D4 inhalation challenge in asthmatics. Effect of a novel leukotriene D4/E4-antagonist (SR 2640) on leukotriene D4-induced bronchoconstriction. Effect of the leukotriene LTD4/LTE4 antagonist, SR 2640, in ulcerative colitis: an open clinical study. Allergy 1991, 46, 355-361.
285. Nielsen, O. H.; Ahnfeltronne, I.; Thomsen, M. K.; Kissmeyer, A. M.; Langholz, E. Effect of the leukotriene LTD4 or LTE4 antagonist, SR-2640, in ulcerative colitis - An open clinical study. Prostaglandins, Leukotrienes, Essential Fatty Acids 1991, 42, 181-184.
286. 4 receptor antagonists: A brief review of the SAR and biologic profile of RG-12525. Drugs Future 1991, 16, 1121-1127.
287. Wahedna, I.; Wisniewski, A. S.; Tattersfield, A. E. Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma. Br. J. Clin. Pharmacol. 1991, 32, 512-515.
288. Jones, T. R.; Zamboni, R.; Belley, M.; Champion, E.; Charette, L.; Ford-Hutchinson, A. W.; Frenette, R.; Gauthier, J. Y.; Leger, S.; Masson, P.; et al. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol. 1989, 67, 17-28.
289. Jones, T. R.; Zamboni, R.; Belley, M.; Champion, E.; Charette, L.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Leger, S.; Lord, A.; Masson, P.; McFarlane, C. S.; Metters, K. M.; Pickett, C.; Piechuta, H.; Young, R. N. Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571. Can. J. Physiol. Pharmacol. 1991, 69, 1847-1854.
290. Yamai, T.; Watanabe, S.; Motojima, S.; Fukuda, T.; Kakino, S. The significance of leukotriene in antigen-induced late asthmatic response. Am. Rev. Respir. Dis. 1989, 139, A462.
291. Pace, D.; Molle, M,; Massarella, J.; Paull, B. Early and late bronchospasm induced by inhalation of nebulized Ro-23-3544 a new leukotriene receptor antagonist in mildly asthmatic patients. J. Allergy Clin. Immunol. 1989, 83, 205.
292. 4-induced granulocyte trafficking in guinea pig dermis. Inflammation 1993, 17, 353-360.
293. 4 receptor antagonist. J. Med. Chem. 1989, 32, 1145-1147.
294. 4. 2. Structure-activity relationships of the lipophilic side chain. J. Med. Chem. 1990, 33, 2807-2813.
295. 4 induced neutrophil activation by LY223982. J. Pharmacol. Exp. Ther. 1992, 263, 1009-1014.
296. 4 Antagonists as Potential Therapeutic Agents, New York, 1994.
297. 4 antagonists in the mouse ear edema model and rat neutropenia model. 7th International Conference of the Inflammation Research Association, White Haven, PA, 1994; P34.